Lexaria Bioscience Corp (LEXX) FinancialsLEXXLexaria Bioscience Corp

Lexaria Bioscience Corp (LEXX) generates its revenue primarily from IP Licensing, which accounts for 100.0% of total sales, equivalent to $84.00K. Understanding this concentration is critical for investors evaluating how LEXX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Lexaria Bioscience Corp maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25096.69%, while the net margin is -25216.08%. These profitability ratios, combined with a Return on Equity (ROE) of -150.28%, provide a clear picture of how effectively LEXX converts its operational activities into shareholder value.

In the context of the broader market, LEXX competes directly with industry leaders such as TPST and RKTO. With a market capitalization of $18.64M, it holds a leading position in the sector. When comparing efficiency, LEXX's gross margin of 100.00% stands against TPST's N/A and RKTO's N/A. Such benchmarking helps identify whether Lexaria Bioscience Corp is trading at a premium or discount relative to its financial performance.

Lexaria's total revenue for Q2 2026 was only $20,000, with a net income loss of $1,449,979, reflecting ongoing financial struggles. The gross margin remains high at 100%, but the overall profitability is severely impacted by consistent net losses.